The expectation of perfection: Risk of blood clot from Johnson & Johnson COVID-19 vaccine is 0.00009% MarketWatch 8 hrs ago
DISPATCHES FROM A PANDEMIC © MarketWatch photo illustration/iStockphoto The suspension of a vaccine runs the risk of affecting public opinion surrounding the entire process.
Achieving herd immunity through mass vaccination involves a delicate sometimes tricky dance with side effects, public opinion and virus variants. All three are unpredictable, and can turn when you least expect it.
Popular Searches
The rollout of coronavirus vaccines has not been without challenges, but the government’s goal to not rely on just one vaccine has limited the scope of a setback involving any one product. As this week’s events illustrate, however, the suspension of a vaccine runs the risk of affecting public opinion surrounding the entire process.
What Johnson & Johnson and AstraZeneca s problems reveal about the COVID-19 mass-vaccination campaign
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Johnson & Johnson and AstraZeneca problems are not unexpected — it would be more unusual to have NO vaccine problems
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
The Philadelphia Inquirer
Star Tribune
Vials are inspected at Regeneron Pharmaceutical’s facilities in New York state, for efforts on an experimental coronavirus antibody drug.
TribLIVE s Daily and Weekly email newsletters deliver the news you want and information you need, right to your inbox.
PHILADELPHIA Drugs that can keep high-risk covid-19 patients out of the hospital are going begging because the supposed breakthrough treatments require an hour-long intravenous infusion and offer a rather small chance of benefit.
On Monday, Regeneron announced results that may help make its monoclonal antibody combination, now branded REGEN-COV, more useful. The drug combo was given in a single shot and dramatically reduced the chance of infection in unvaccinated individuals living with someone newly diagnosed with covid-19.